Question 1

What is Ipamorelin?

Accepted Answer

Ipamorelin is a synthetic pentapeptide growth hormone releasing peptide (GHRP) that selectively stimulates growth hormone release from the pituitary gland. Developed in the 1990s by Novo Nordisk, it is considered one of the mildest and most selective GHRPs available. Unlike older GHRPs such as GHRP-6 and Hexarelin, Ipamorelin does not significantly elevate cortisol, prolactin, or appetite.

Question 2

What are the research benefits of Ipamorelin?

Accepted Answer

Research on Ipamorelin has investigated its potential effects in several areas, including: Selective GH release without cortisol or prolactin elevation; Mimics natural pulsatile GH secretion patterns; Studied for improved body composition and lean mass; Researched for sleep quality enhancement via GH pulse timing. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Ipamorelin work?

Accepted Answer

Ipamorelin binds to the ghrelin receptor (GHS-R1a) on somatotroph cells in the anterior pituitary, triggering growth hormone release in a pulsatile fashion that mimics natural secretion patterns. It does not affect other pituitary hormones at typical research concentrations, which distinguishes it from less selective GHRPs.

Question 4

What is the FDA/legal status of Ipamorelin?

Accepted Answer

Ipamorelin is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of Ipamorelin?

Accepted Answer

Based on available research, Ipamorelin has been associated with the following in study settings: Mild headache at initiation; Transient water retention; Tingling or numbness in extremities; Mild fatigue or drowsiness post-injection. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Ipamorelin?

Accepted Answer

Published research on Ipamorelin can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Ipamorelin" or its aliases (Ipamorelin Acetate, NNC 26-0161) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Ipamorelin

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer